Loading
Chiauranib is an experimental small-molecule drug from Chipscreen Biosciences in phase 3 trials for ovarian cancer, aimed at VEGF / VEGFR and KIT.
Chiauranib (CS2164) is a small-molecule drug developed by Chipscreen Biosciences. Its targets are VEGF / VEGFR, KIT, PDGFRA, CSF1R and Folate receptor alpha (the sponsor names VEGFR1, VEGFR2, VEGFR3, PDGFRa, c-Kit, Aurora B, CSF-1R). The sponsor states: A novel orally active multi-target inhibitor that simultaneously inhibits angiogenesis-related kinases (VEGFR1/2/3, PDGFRa, c-Kit), the mitosis-related kinase Aurora B, and the chronic-inflammation-related kinase CSF-1R at single-digit nanomolar potency. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04921527 (Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer), in ovarian cancer. The largest, NCT04921527, plans to enrol 454 participants with primary completion was scheduled for 2024-12-31 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A novel orally active multi-target inhibitor that simultaneously inhibits angiogenesis-related kinases (VEGFR1/2/3, PDGFRa, c-Kit), the mitosis-related kinase Aurora B, and the chronic-inflammation-related kinase CSF-1R at single-digit nanomolar potency. Connects to VEGF / VEGFR, KIT, PDGFRA, CSF1R and Folate receptor alpha.
1.Chiauranib slips into a pocket on VEGF / VEGFR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Chiauranib" OR ABSTRACT:"Chiauranib" OR TITLE:"CS2164" OR ABSTRACT:"CS2164") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Chiauranib, not a curated reading list.
Shares Folate receptor alpha, Ovarian cancer and the tag pipeline.
Shares Folate receptor alpha, Ovarian cancer and the tag pipeline.
Shares Chipscreen Biosciences and the tag pipeline.
Shares Folate receptor alpha and the tag pipeline.
Shares CSF1R and the tag pipeline.
Shares KIT and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.